By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RuiYi (formerly Anaphore) 

10931 North Torrey Pines Road
Suite 101
La Jolla  California  92037  U.S.A.
Phone: 858-587-4815 Fax: 858-587-4854




Company News
RuiYi (formerly Anaphore) Announces the First Human Dosing Of A Novel Antibody, Gerilimzumab, For The Treatment Of Rheumatoid Arthritis And Other Autoimmune Disorders 9/23/2015 11:23:25 AM
RuiYi (formerly Anaphore) Appoints Mark Saad Chief Financial Officer 9/3/2014 11:42:04 AM
RuiYi (formerly Anaphore) Closes $4 Million Venture Loan From Silicon Valley Bank 6/11/2014 9:49:39 AM
RuiYi (formerly Anaphore) And iHuman Institute Form Collaboration To Identify Novel Antibodies Targeting GPCRs 6/11/2014 9:45:48 AM
Week in Review: RuiYi (formerly Anaphore) Raises $15 Million For mAb Development 3/30/2014 3:04:48 PM
San Diego's RuiYi (formerly Anaphore) Grabs $15 Million For Monoclonal Antibody Research 3/27/2014 7:03:58 AM
Week in Review: RuiYi (formerly Anaphore) Signs Up Shanghai's Genor to Develop mAb in China 5/20/2013 9:24:09 AM
RuiYi (formerly Anaphore) and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer 5/16/2013 10:08:27 AM
CMC Biologics and RuiYi (formerly Anaphore) Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody 5/14/2013 9:28:56 AM
Anaphore Announces Name Change to RuiYi (formerly Anaphore) and New Additions to Shanghai Management Team 10/4/2012 6:45:47 AM